NasdaqGS:IPHS

Stock Analysis Report

Executive Summary

Innophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets.

Snowflake

Fundamentals

Average dividend payer and fair value.

Risks

  • Innophos Holdings is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Innophos Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NasdaqGS:IPHS

-3.2%

US Chemicals

-1.6%

US Market


1 Year Return

-40.3%

NasdaqGS:IPHS

-18.6%

US Chemicals

-3.0%

US Market

IPHS underperformed the Chemicals industry which returned -16.1% over the past year.

IPHS underperformed the Market in United States of America which returned -0% over the past year.


Share holder returns

IPHSIndustryMarket
7 Day0%-3.2%-1.6%
30 Day-3.2%-8.5%-5.8%
90 Day-4.1%-3.8%0.2%
1 Year-36.3%-40.3%-5.7%-18.6%-0.8%-3.0%
3 Year-27.6%-37.6%30.8%6.7%38.0%29.1%
5 Year-42.0%-54.4%26.5%-1.1%50.8%34.1%

Price Volatility Vs. Market

How volatile is Innophos Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innophos Holdings undervalued based on future cash flows and its price relative to the stock market?

17.93x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Innophos Holdings's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Innophos Holdings's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Innophos Holdings is good value based on earnings compared to the US Chemicals industry average.

Innophos Holdings is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Innophos Holdings is good value based on expected growth next year.


Price Based on Value of Assets

Innophos Holdings is good value based on assets compared to the US Chemicals industry average.


Next Steps

Future Growth

How is Innophos Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

37.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Innophos Holdings's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Innophos Holdings's earnings are expected to grow significantly at over 20% yearly.

Innophos Holdings's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Innophos Holdings's earnings growth is expected to exceed the United States of America market average.

Innophos Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Innophos Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Innophos Holdings performed over the past 5 years?

-18.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Innophos Holdings's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Innophos Holdings's 1-year earnings growth exceeds its 5-year average (65.6% vs -18.3%)

Innophos Holdings's earnings growth has exceeded the US Chemicals industry average in the past year (65.6% vs -2.4%).


Return on Equity

Innophos Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Innophos Holdings used its assets less efficiently than the US Chemicals industry average last year based on Return on Assets.


Return on Capital Employed

Innophos Holdings's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Innophos Holdings's financial position?


Financial Position Analysis

Innophos Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Innophos Holdings's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Innophos Holdings's level of debt (98.4%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (29.2% vs 98.4% today).

Debt is well covered by operating cash flow (24.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1x debt.


Next Steps

Dividend

What is Innophos Holdings's current dividend yield, its reliability and sustainability?

7.25%

Current Dividend Yield


Dividend Yield and Payments Analysis

Innophos Holdings's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.49%).

Innophos Holdings's dividend is above the markets top 25% of dividend payers in United States of America (3.82%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are not well covered by earnings (0.8x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Innophos Holdings's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Kim Mink (59yo)

3.7yrs

Tenure

US$3,353,966

Compensation

Dr. Kim Ann Mink, Ph.D., has been the Chief Executive Officer and President at Innophos Holdings Inc. since December 14, 2015. Dr. Mink serves as the President of CanStates Holdings, Inc. She has been a Di ...


CEO Compensation Analysis

Kim's remuneration is higher than average for companies of similar size in United States of America.

Kim's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.3yrs

Average Tenure

59yo

Average Age

The tenure for the Innophos Holdings management team is about average.


Board Age and Tenure

7.0yrs

Average Tenure

63yo

Average Age

The tenure for the Innophos Holdings board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Mark Feuerbach (60yo)

    Chief Financial Officer

    • Tenure: 0.4yrs
    • Compensation: US$752.26k
  • Kim Mink (59yo)

    Chairman of the Board

    • Tenure: 3.7yrs
    • Compensation: US$3.35m
  • James Testa (71yo)

    Assistant Secretary

    • Tenure: 0.0yrs
  • Sherry Duff (51yo)

    Senior VP and Chief Marketing & Technology Officer

    • Tenure: 3.1yrs
    • Compensation: US$724.63k
  • Yasef Murat (64yo)

    Senior Manufacturing Fellow

    • Tenure: 2.3yrs
    • Compensation: US$570.29k
  • Mark Santangelo (61yo)

    Senior Vice President of Manufacturing

    • Tenure: 2.3yrs
    • Compensation: US$776.54k
  • Josh Horenstein (42yo)

    Senior VP

    • Tenure: 3.4yrs
    • Compensation: US$814.35k
  • Amy Hartzell (43yo)

    Senior Vice President of Supply Chain & Purchasing

    • Tenure: 2.3yrs
    • Compensation: US$537.56k
  • William Dunworth (43yo)

    VP, Corporate Controller & Chief Accounting Officer

    • Tenure: 0.8yrs

Board Members

  • John Steitz (60yo)

    Independent Director

    • Tenure: 10.5yrs
    • Compensation: US$209.64k
  • Karen Osar (70yo)

    Independent Director

    • Tenure: 11.8yrs
    • Compensation: US$198.19k
  • Gary Cappeline (69yo)

    Director

    • Tenure: 12.6yrs
    • Compensation: US$234.82k
  • Bob Zatta (69yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$208.05k
  • Peter Thomas (63yo)

    Lead Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$218.76k
  • Linda Myrick (63yo)

    Independent Director

    • Tenure: 12.8yrs
    • Compensation: US$188.92k
  • Kim Mink (59yo)

    Chairman of the Board

    • Tenure: 3.7yrs
    • Compensation: US$3.35m
  • Jane Hilk (59yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$10.87k

Company Information

Innophos Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innophos Holdings, Inc.
  • Ticker: IPHS
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: US$517.681m
  • Shares outstanding: 19.54m
  • Website: https://www.innophos.com

Number of Employees


Location

  • Innophos Holdings, Inc.
  • 259 Prospect Plains Road
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPHSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2006
HQ9DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006
IPHS *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2006

Biography

Innophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Healt ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 00:10
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.